Aden.Ns
ADEN.NS is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.
Business. ADEN.NS is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ADEN.NS is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.
ADEN.NS maintains a strong liquidity position, with a current ratio of 9.09 and cash and equivalents of INR 667.5 million. The company's debt-to-equity ratio is 0.03, indicating a low reliance on debt financing and a strong equity base. The operating cash flow of INR 1.425 billion and free cash flow of INR 776.92 million further support its ability to fund operations and invest in growth without significant external financing.
In terms of profitability, ADEN.NS reports a return on equity (ROE) of 9.15% and a return on assets (ROA) of 8.09%. These figures are strong relative to the industry's typical performance, suggesting efficient use of equity and assets to generate returns. The company's operating income of INR 1.579 billion and net income of INR 1.311 billion reflect solid operational performance.
ADEN.NS operates as a single-segment company, with all revenue derived from the sale of specialty chemicals. The company's geographic exposure is not disclosed in the available data, but the lack of segment or geographic breakdown suggests a relatively concentrated business model.
The company's growth trajectory is supported by its strong cash flow generation and profitability. While specific revenue growth rates are not provided, the company's operating cash flow and free cash flow indicate a capacity for reinvestment and expansion. The capital expenditure of INR 338.08 million suggests ongoing investment in infrastructure and operations.
ADEN.NS faces low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves reduce the likelihood of liquidity constraints. Additionally, the absence of dilution risks suggests that the company is not currently issuing new shares to raise capital, preserving shareholder value.
Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. Analysts have provided a mean price target of INR 370.00, with a single "buy" recommendation and no "strong buy" or "hold" ratings. This suggests a generally positive outlook from the investment community, albeit with limited enthusiasm.
- ADEN.NS has a strong liquidity position with a current ratio of 9.09 and significant cash reserves.
- The company's ROE of 9.15% and ROA of 8.09% indicate efficient use of equity and assets.
- ADEN.NS operates as a single-segment company with no disclosed geographic diversification.
- The company's capital expenditure of INR 338.08 million suggests ongoing investment in operations.
- Analysts have provided a mean price target of INR 370.00, with a single "buy" recommendation.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 13,60 |
| Revenue | —no estimate | —no estimate | 7,3B INR |
| Operating income | —no estimate | —no estimate | 1,8B INR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ADEN.NS Market data — financials · 2026-05-27
- Advanced Enzyme Technologies Ltd Market data — analyst estimates · 2026-05-27